A comparative characterization of cooperation and quality of life of bronchial asthma patients using different dosed aerosol delivery systems
Abstract
Therapy efficacy depends directly on a patient’s keeping of all medical recommendations. The concept of cooperation between a patient and a doctor is quite new in the medicine. The "compliance" term used before can not reproduce relations between a patient and a doctor or between a patient or a healthcare system in detail; it is relevant to a patient's attachment to a treatment mode. This fact made to seek new ways describing the cooperation of a patient and a doctor and resulted in creation of the "cooperation" term and lcBA-50 questionnaire.
The cooperation should obviously change when applying new BA therapeutic or detecting techniques. Taking into account supply of new aerosol drug delivery systems to the home pharmaceutical market it was reasonable to study dynamically the cooperation and the quality of life (QL) under patients' transferring to such the drugs.
The cooperation was evaluated using the lcBA-50 questionnaire which includes 50 points to quantify the cooperation according to 8 principal criteria and a ratings sum method. The QLwas assessed using the SF-36 questionnaire including 36 points and 7 criteria.
The present work shows that the most convenient drug delivery systems and dosing mode can considerably increase a patient's cooperation and QL. But such important points as a patient's keeping of a doctor's recommendations and factors influencing cooperation of a patient and a doctor were not involved in the study of the QL. Results allowed to define a doctor’s principal actions to optimize his cooperation with a patient.
About the Authors
A. S. Belevsky
НИИ пульмонологии Минздрава РФ
Russian Federation
Russian Federation
N. N. Mescheryakova
НИИ пульмонологии Минздрава РФ
Russian Federation
Russian Federation
References
1. Белевский A.C., Булкина Л.C., Княжеская Н.П. Обучение больных бронхиальной астмой как метод улучшения результатов лечения. В кн.: 6-й Национальный конгресс по болезням органов дыхания. М.: 1996. No 1123.
2. Буйневич К.А. Руководство к изучению внутренних болезней. Калуга: губернская типолитография: 1909.
3. Вотчал Б.Е. Очерки клинической фармакологии. М.: Медгиз; 1963. 17-39.
4. Гаркалов К.А. Психосоциальное значение астма-школ. В кн.: Национальный конгресс по болезням органов дыхания, 6-й. М.; 1996. No 125.
5. Кассирский И.А. О врачевании. М.: Медицина; 1970.
6. Пезешкиан Н. Психосоматика и позитивная психотерапия. М.: Медицина; 1996. 33-71.
7. Сенкевич Н.Ю. Качество жизни и кооперативность больных бронхиальной астмой. Автореф. ... д-ра мед. наук. 2000.
8. Сербский В.П. Руководство к изучению душевных болезней. М.; 1906. 308-451.
9. Федосеев Г.Б., Крякунов К.Н. Лекарственная терапия: что, кому, как, когла, с какой целыо? В мире лекарств 2000; 1: 4-8.
10. Фейдман Д., Фрейгер Р. Личность и личностный рост. М.: Изд. Рос. открытого ун-та; 1992.
11. Чучалин А.Г. Бронхиальная астма. М.: Агар; 1997; 1: 424-429.
12. Юдин Б.Г., Тищенко П.Д., Игнатьев В.И. Этиологические и правовые проблемы клинических испытаний и научных экспериментов на человеке и животных. М.: РНКБ РАН; 1994.
13. Bousquet J., Ktiani J., Dhivert H. et al. Quality of life in asthma. Internal consistency and validity of the SF-36 questionnaire. Am. J. Respir. Crit. Care Med. 1994; 149: 371-375.
14. Chemplik F., Doughty A. Objective measurements of compliance in asthma treatment. Ann. Allergy 1994; 73: 537-532.
15. Cochrane G.M. Compliance in asthma; a European perspective. Eur. Respir. J. 1995; 10 (5): 116-119.
16. Cochrane G.M. Compliance in asthma. Eur. Respir. Rev. 1998; 8 (56): 239-242.
17. Engel G.E. The clinical application of the biopsychosocial model. Am. J. Psychiatry 1980; 137: 535-543.
18. Horn C.R., Clark T.J.H., Cochrane G.M. Compliance with inhaled therapy and morbidity from astma. Respir. Med. 1990; 84: 67-70.
19. Jambon B., Johnson K.I. Individual quality of life and clinical trials. News Letter QOL 1997; 17: 2-17.
20. Jones P.W., Quirk F.H., Baueystock C.M., Littlejohns P. Why quality ot lite measures should be used in the treatment of patients with respiratory illnesses. Monaldi Arch. Dis. Chest 1994; 49: 79-82.
21. Juniper E.F., Guyatt G.H., Willan A., Griffith L.E. Determininq a minimal important change in a disease-specific QOL questionnaire. J. Clin. Epidemiol. 1994; 47 (1): 81-87.
22. Karnolsky D.F., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in Cancer. In: Maclead C.M., ed. Evaluation of chemotherapeutic agents. Washington: Columbia University Press; 1947. 107-134.
23. Kinsman R.A., Dirks J.F., Dahlem N.W. Noncompliance to pre- scribed-as-needed medication use in asthma: usage patterns and patient characteristics. J. Psychosom. Res. 1980; 24: 97-101.
24. Mahajan P., Okamoto L.J., Schaberg A. Impact of fluticasone propionate powder health-related quality of life in palated quality of life in patients with moderate asthma. J. Asthma 1997; 34: 227-234.
25. Maslow A.H. Motivaion and personality. New York: Harper& Brothers, 1954. 241-246.
26. McSweeny A.J., Gramt I., Heaton R.K. et al. Life quality of patients with chronic obstructiv pulmonary disease. Arch. Intern. Med. 1982; 142: 473-478.
27. Patrick D. Quality of life and pharmacoeconomic evaluation. News Letter QOL 1998; spec, issue: 6-7.
28. Sherbourne C.D. Pain measures. In: Stewart A.L., Ware J.E. et.al. Measuring functioning and well-being: The medical outcomes study approach. Durham, N.C.: Duke University Press; 1992.
29. Varshavsky S. Quality of life research in Russia. News Letter Qol. 2000; 25: 13.
30. The WHO QOL Group. What Quality of life? Wld Hlth Forum 1996; 17 (4): 354-356.
Review
For citations:
Belevsky A.S., Mescheryakova N.N. A comparative characterization of cooperation and quality of life of bronchial asthma patients using different dosed aerosol delivery systems. PULMONOLOGIYA. 2003;(2):42-48. (In Russ.)
Views:
219
Email this article 